Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Multi-arm, Open Label Study to Assess the Safety and Efficacy of EP0057 in Combination With Olaparib in Defined Populations of Patients With Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

Trial Profile

A Phase 2 Multi-arm, Open Label Study to Assess the Safety and Efficacy of EP0057 in Combination With Olaparib in Defined Populations of Patients With Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EP-0057 (Primary) ; Olaparib (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Ellipses Pharma

Most Recent Events

  • 09 Jun 2023 Status changed from not yet recruiting to withdrawn prior to enrolment. Reason the study was stopped: Futility analysis decision to terminate EP0057 compound and all Ellipses sponsored studies involving EP0057.
  • 01 Nov 2022 Planned initiation date changed from 1 Jul 2022 to 1 Apr 2023.
  • 14 Jun 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top